Cutaneous graft-versus-host disease: a guide for the dermatologist.
Graft-versus-host disease (GVHD) is defined by the aggregation of clinical and pathological manifestations in a recipient of allogeneic stem cells or bone marrow transplantation in which specific immunological as well as nonspecific phenomena lead to characteristic features. GVHD is one of the major complications after hematopoietic stem cell transplantations and responsible for posttherapeutic morbidity, mortality and decrease in quality of life of those patients. GVHD is critically induced and maintained by donor immunocompetent cells that particularly attack epithelia of fast proliferating tissues such as those from the liver, gastrointestinal tract and skin. On the basis of the time of presentation, cutaneous GVHD has been originally divided into an acute and chronic disease. The latter has traditionally been further subclassified into a more epithelial or lichenoid and a predominantly dermal or sclerodermoid form. With respect to the growing importance of this therapeutic procedure and increasing numbers of outpatients presenting with chronic GVHD, this article summarizes the updated knowledge on this disease focused for the dermatologist, and additionally it emphasizes the recent consensus documents on the various aspects of chronic GVHD of the National Institute of Health.
Häusermann
Peter
P
Department of Dermatology, University Hospital Basel, Basel, Switzerland. phaeusermann@uhbs.ch
Walter
Roland B
RB
Halter
Jörg
J
Biedermann
Barbara C
BC
Tichelli
André
A
Itin
Peter
P
Gratwohl
Alois
A
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002908:Chronic Disease / Q000628:therapy; D006086:Graft vs Host Disease / Q000145:classification / Q000188:drug therapy / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use
D007166:Immunosuppressive Agents